These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 12574959)

  • 1. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
    Wierzbowska A; Urbańska-Ryś H; Robak T
    Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
    Keyes KA; Mann L; Cox K; Treadway P; Iversen P; Chen YF; Teicher BA
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):321-7. PubMed ID: 12721760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
    Edgren M; Lennernäs B; Larsson A; Kälkner KM
    Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
    Salgado R; Vermeulen PB; Benoy I; Weytjens R; Huget P; Van Marck E; Dirix LY
    Br J Cancer; 1999 May; 80(5-6):892-7. PubMed ID: 10360671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
    Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
    Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma.
    Ho CL; Sheu LF; Li CY
    Ann Diagn Pathol; 2003 Feb; 7(1):1-8. PubMed ID: 12616467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.
    Lissoni P; Malugani F; Bonfanti A; Bucovec R; Secondino S; Brivio F; Ferrari-Bravo A; Ferrante R; Vigoré L; Rovelli F; Mandalà M; Viviani S; Fumagalli L; Gardani GS
    J Biol Regul Homeost Agents; 2001; 15(2):140-4. PubMed ID: 11501971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
    Shang ZJ; Li JR; Li ZB
    Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
    Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.